Delaware | 46-3640387 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification No.) |
Large accelerated filer ☒ | Accelerated filer ☐ |
Non-accelerated filer ☐ | Smaller reporting company ☐ |
(Do not check if a smaller reporting company) | Emerging growth company ☐ |
Class | Number of Shares Outstanding | |
Common Stock $0.01 par value | 63,369,729 shares outstanding as of October 23, 2017 |
Item Number | Page | |
September 30, | December 31, | |||||||
2017 | 2016 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 193,581 | $ | 144,623 | ||||
Restricted cash | 697 | 4,715 | ||||||
Accounts receivable and unbilled services, net | 628,029 | 439,053 | ||||||
Other current assets | 70,361 | 36,346 | ||||||
Total current assets | 892,668 | 624,737 | ||||||
Fixed assets, net | 131,432 | 87,577 | ||||||
Goodwill | 1,535,057 | 971,980 | ||||||
Intangible assets, net | 711,727 | 473,976 | ||||||
Other assets | 38,749 | 32,121 | ||||||
Total assets | $ | 3,309,633 | $ | 2,190,391 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Current portion of long-term debt | $ | 56,719 | $ | 31,250 | ||||
Accounts payable | 60,438 | 51,335 | ||||||
Accrued expenses and other current liabilities | 277,495 | 149,113 | ||||||
Advanced billings | 493,368 | 332,501 | ||||||
Total current liabilities | 888,020 | 564,199 | ||||||
Long-term debt, net | 1,293,498 | 797,052 | ||||||
Deferred tax liabilities | 128,366 | 73,703 | ||||||
Other long-term liabilities | 63,452 | 26,185 | ||||||
Total liabilities | 2,373,336 | 1,461,139 | ||||||
Commitments and contingencies (Note 11) | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, $0.01 par value, 100,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively | — | — | ||||||
Common stock, $0.01 par value, 1,000,000,000 authorized shares at September 30, 2017 and December 31, 2016; 63,329,298 and 61,597,705 issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 633 | 616 | ||||||
Additional paid-in capital | 898,862 | 879,067 | ||||||
Accumulated other comprehensive loss | (146,291 | ) | (224,686 | ) | ||||
Retained earnings | 177,230 | 74,255 | ||||||
Equity attributable to PRA Health Sciences, Inc. stockholders | 930,434 | 729,252 | ||||||
Noncontrolling interest | 5,863 | — | ||||||
Total stockholders' equity | 936,297 | 729,252 | ||||||
Total liabilities and stockholders' equity | $ | 3,309,633 | $ | 2,190,391 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Revenue: | ||||||||||||||||
Service revenue | $ | 494,550 | $ | 399,841 | 1,379,572 | $ | 1,166,410 | |||||||||
Reimbursement revenue | 87,459 | 53,414 | 223,921 | 172,915 | ||||||||||||
Total revenue | 582,009 | 453,255 | 1,603,493 | 1,339,325 | ||||||||||||
Operating expenses: | ||||||||||||||||
Direct costs | 326,865 | 259,910 | 914,988 | 758,333 | ||||||||||||
Reimbursable out-of-pocket costs | 87,459 | 53,414 | 223,921 | 172,915 | ||||||||||||
Selling, general and administrative | 79,307 | 67,190 | 229,770 | 199,648 | ||||||||||||
Transaction-related costs | 12,740 | — | 12,740 | 31,785 | ||||||||||||
Depreciation and amortization | 18,853 | 17,708 | 50,146 | 52,246 | ||||||||||||
Loss on disposal of fixed assets, net | 8 | 219 | 240 | 290 | ||||||||||||
Income from operations | 56,777 | 54,814 | 171,688 | 124,108 | ||||||||||||
Interest expense, net | (11,557 | ) | (13,779 | ) | (31,088 | ) | (42,525 | ) | ||||||||
Loss on modification or extinguishment of debt | (3,089 | ) | — | (3,089 | ) | (21,485 | ) | |||||||||
Foreign currency (losses) gains, net | (12,794 | ) | 1,182 | (35,004 | ) | 9,264 | ||||||||||
Other income (expense), net | 1,004 | 20 | 724 | (85 | ) | |||||||||||
Income before income taxes and equity in income of unconsolidated joint ventures | 30,341 | 42,237 | 103,231 | 69,277 | ||||||||||||
(Benefit from) provision for income taxes | (18,241 | ) | 10,821 | (165 | ) | 17,869 | ||||||||||
Income before equity in income of unconsolidated joint ventures | 48,582 | 31,416 | 103,396 | 51,408 | ||||||||||||
Equity in income of unconsolidated joint ventures, net of tax | 24 | 33 | 92 | 2,742 | ||||||||||||
Net income | 48,606 | 31,449 | 103,488 | 54,150 | ||||||||||||
Net income attributable to noncontrolling interest | (401 | ) | — | (513 | ) | — | ||||||||||
Net income attributable to PRA Health Sciences, Inc. | $ | 48,205 | $ | 31,449 | $ | 102,975 | $ | 54,150 | ||||||||
Net income per share attributable to common stockholders: | ||||||||||||||||
Basic | $ | 0.77 | $ | 0.52 | $ | 1.66 | $ | 0.89 | ||||||||
Diluted | $ | 0.73 | $ | 0.49 | $ | 1.57 | $ | 0.84 | ||||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 62,730 | 60,937 | 62,185 | 60,579 | ||||||||||||
Diluted | 65,872 | 64,521 | 65,683 | 64,268 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Net income | $ | 48,606 | $ | 31,449 | $ | 103,488 | $ | 54,150 | ||||||||
Other comprehensive income (loss): | ||||||||||||||||
Foreign currency translation adjustments | 26,863 | (11,211 | ) | 75,076 | (55,548 | ) | ||||||||||
Unrealized income (loss) on derivative instruments, net of income tax of $(11), $0, $(11) and $0 | 46 | 127 | (21 | ) | (2,546 | ) | ||||||||||
Reclassification adjustments: | ||||||||||||||||
(Gain) loss on derivatives included in net income, net of income taxes of $1,926, $0, $1,926 and $0 | (167 | ) | 1,617 | 3,249 | 4,242 | |||||||||||
Comprehensive income | 75,348 | 21,982 | 181,792 | 298 | ||||||||||||
Comprehensive income attributable to noncontrolling interest | (373 | ) | — | (423 | ) | — | ||||||||||
Comprehensive income attributable to PRA Health Sciences, Inc. | $ | 74,975 | $ | 21,982 | $ | 181,369 | $ | 298 |
Nine Months Ended September 30, | ||||||||
2017 | 2016 | |||||||
Cash flows from operating activities: | ||||||||
Net income | $ | 103,488 | $ | 54,150 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 50,146 | 52,246 | ||||||
Amortization of debt issuance costs and discount | 1,480 | 3,514 | ||||||
Amortization of terminated interest rate swaps | 4,931 | 3,334 | ||||||
Stock-based compensation | 7,686 | 4,940 | ||||||
Non-cash transaction-related costs | 5,294 | 29,421 | ||||||
Unrealized foreign currency losses (gains) | 35,406 | (9,380 | ) | |||||
Loss on modification or extinguishment of debt | 3,089 | 21,485 | ||||||
Deferred income taxes | (27,340 | ) | (8,076 | ) | ||||
Equity in income of unconsolidated joint ventures | (92 | ) | (2,742 | ) | ||||
Other reconciling items | 190 | 41 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable, unbilled services, and advanced billings | (51,883 | ) | (52,290 | ) | ||||
Other operating assets and liabilities | (14,567 | ) | (29,935 | ) | ||||
Net cash provided by operating activities | 117,828 | 66,708 | ||||||
Cash flows from investing activities: | ||||||||
Purchase of fixed assets | (39,287 | ) | (25,657 | ) | ||||
Cash paid for interest on interest rate swap | (763 | ) | (913 | ) | ||||
Proceeds from the sale of WuXiPRA | — | 3,700 | ||||||
Proceeds from the sale of fixed assets | 55 | — | ||||||
Acquisition of Symphony Health Solutions Corporation, net of cash acquired | (522,581 | ) | — | |||||
Acquisition of Parallel 6, Inc., net of cash acquired | (39,561 | ) | — | |||||
Acquisition of Takeda PRA Development Center KK, net of cash acquired | 2,680 | — | ||||||
Acquisition of Takeda Pharmaceutical Data Services, Ltd., net of cash acquired | (142 | ) | — | |||||
Acquisition of Nextrials, Inc., net of cash acquired | — | (4,268 | ) | |||||
Net cash used in investing activities | (599,599 | ) | (27,138 | ) | ||||
Cash flows from financing activities: | ||||||||
Borrowings on accounts receivable financing agreement | 20,000 | 120,000 | ||||||
Repayments on accounts receivable financing agreement | (20,000 | ) | — | |||||
Proceeds from issuance of long-term debt | 550,000 | — | ||||||
Repayments of long-term debt | (26,875 | ) | (133,559 | ) | ||||
Borrowings on line of credit | 30,000 | 110,000 | ||||||
Repayments on line of credit | (30,000 | ) | (110,000 | ) | ||||
Payments for debt issuance costs | (5,512 | ) | — | |||||
Payment of debt prepayment and debt extinguishment costs | — | (17,824 | ) | |||||
Proceeds from stock option exercises | 6,457 | 638 | ||||||
Payment of acquisition-related contingent consideration | (400 | ) | — | |||||
Net cash provided by (used in) financing activities | 523,670 | (30,745 | ) | |||||
Effects of foreign exchange changes on cash, cash equivalents, and restricted cash | 3,041 | 628 | ||||||
Change in cash, cash equivalents, and restricted cash | 44,940 | 9,453 | ||||||
Cash, cash equivalents, and restricted cash, beginning of period | 149,338 | 126,125 | ||||||
Cash, cash equivalents, and restricted cash, end of period | $ | 194,278 | $ | 135,578 |
September 30, | December 31, | |||||||||||||||
2017 | 2016 | 2016 | 2015 | |||||||||||||
Cash and cash equivalents | $ | 193,581 | $ | 130,343 | $ | 144,623 | $ | 121,065 | ||||||||
Restricted cash | 697 | 5,235 | 4,715 | 5,060 | ||||||||||||
Total cash, cash equivalents, and restricted cash | $ | 194,278 | $ | 135,578 | $ | 149,338 | $ | 126,125 |
Purchase Price Allocation | Weighted Amortization Period | |||||
Cash and cash equivalents | $ | 26,297 | ||||
Accounts receivable | 39,056 | |||||
Other current assets | 24,048 | |||||
Fixed assets | 12,340 | |||||
Software and other intangibles | 13,000 | 5 years | ||||
Database | 64,600 | 9 years | ||||
Customer relationships | 161,000 | 12 years | ||||
Accounts payable and accrued expenses | (42,700 | ) | ||||
Deferred revenue | (65,511 | ) | ||||
Deferred tax liabilities | (75,056 | ) | ||||
Other long-term liabilities | (7,940 | ) | ||||
Estimated fair value of net assets acquired | 149,134 | |||||
Purchase price, including contingent consideration | 649,609 | |||||
Total goodwill | $ | 500,475 |
Nine Months Ended September 30, | |||||||
(in thousands, except per share amounts) | 2017 | 2016 | |||||
Total revenue | $ | 1,752,514 | $ | 1,484,013 | |||
Net income attributable to PRA Health Sciences, Inc. | 126,092 | 35,830 | |||||
Net income per share: | |||||||
Basic | $ | 2.03 | $ | 0.59 | |||
Diluted | $ | 1.92 | $ | 0.56 |
• | a $6.4 million increase to transaction-related costs incurred by the Company during the nine months ended September 30, 2017 attributable to the transaction, with a corresponding $2.5 million increase to the benefit from income taxes. |
• | a $3.1 million increase to loss on the modification or extinguishment of long-term debt incurred by the Company during the nine months ended September 30, 2017 attributable to the above transaction, with a corresponding $1.2 million increase to the benefit from income taxes. |
Purchase Price Allocation | ||||
Cash and cash equivalents | $ | 8,120 | ||
Other current assets | 1,671 | |||
Other non-current assets | 1,742 | |||
Accounts payable and accrued expenses | (2,380 | ) | ||
Other long-term liabilities | (943 | ) | ||
Estimated fair value of net assets acquired | 8,210 | |||
PRA purchase price | 5,440 | |||
Fair value of Takeda's noncontrolling interest | 5,440 | |||
Total goodwill | $ | 2,670 |
Purchase Price Allocation | Weighted Amortization Period | |||||
Cash and cash equivalents | $ | 132 | ||||
Accounts receivable | 1,231 | |||||
Other current assets | 26 | |||||
Software intangible | 15,500 | 5 years | ||||
Other intangibles | 920 | 5 years | ||||
Accounts payable and accrued expenses | (885 | ) | ||||
Deferred revenue | (994 | ) | ||||
Other long-term liabilities | (2,414 | ) | ||||
Estimated fair value of net assets acquired | 13,516 | |||||
Purchase price, including contingent consideration | 46,652 | |||||
Total goodwill | $ | 33,136 |
Purchase Price Allocation | Weighted Amortization Period | |||||
Cash and cash equivalents | $ | 94 | ||||
Accounts receivable | 211 | |||||
Other current assets | 96 | |||||
Property, plant and equipment | 111 | |||||
Software intangible | 5,574 | 5 years | ||||
Accounts payable and accrued expenses | (1,585 | ) | ||||
Other long-term liabilities | (1,663 | ) | ||||
Estimated fair value of net assets acquired | 2,838 | |||||
Purchase price, including contingent consideration and net of working capital settlement | 7,145 | |||||
Total goodwill | $ | 4,307 |
• | Level 1 — Quoted prices in active markets for identical assets or liabilities. |
• | Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. |
• | Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. |
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Assets: | ||||||||||||||||
Interest rate swap | $ | — | $ | 73 | $ | — | $ | 73 | ||||||||
Marketable securities | 366 | — | — | 366 | ||||||||||||
Total | $ | 366 | $ | 73 | $ | — | $ | 439 | ||||||||
Liabilities: | ||||||||||||||||
Contingent consideration | $ | — | $ | — | $ | 118,564 | $ | 118,564 | ||||||||
Total | $ | — | $ | — | $ | 118,564 | $ | 118,564 |
Contingent Consideration - Accrued expenses and other liabilities | Contingent Consideration - Other long-term liabilities | |||||||
Balance at December 31, 2016 | $ | 1,735 | $ | 1,019 | ||||
Initial estimate of Symphony Health contingent consideration | 90,394 | 18,390 | ||||||
Initial estimate of Parallel 6 contingent consideration | — | 8,350 | ||||||
Payments on Nextrials contingent consideration | (400 | ) | — | |||||
Reclassification adjustment | 1,019 | (1,019 | ) | |||||
Change in fair value recognized in other (income) expense, net | (924 | ) | — | |||||
Balance at September 30, 2017 | $ | 91,824 | $ | 26,740 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||
Customer A | 10.1 | % | 11.7 | % | 10.6 | % | 10.8 | % | ||||
Customer B | — | 10.4 | % | — | 10.7 | % | ||||||
Customer C | — | 10.2 | % | — | — |
September 30, | December 31, | |||||
2017 | 2016 | |||||
Customer A | 10.7 | % | 12.0 | % |
September 30, | December 31, | |||||||
2017 | 2016 | |||||||
Accounts receivable | $ | 457,306 | $ | 284,647 | ||||
Unbilled services | 172,152 | 155,609 | ||||||
629,458 | 440,256 | |||||||
Less allowance for doubtful accounts | (1,429 | ) | (1,203 | ) | ||||
Total accounts receivable and unbilled services, net | $ | 628,029 | $ | 439,053 |
Clinical Research | Data Solutions | Consolidated | |||||||||
Balance at December 31, 2016 | $ | 971,980 | $ | — | $ | 971,980 | |||||
Acquisition of Symphony Health | — | 500,475 | 500,475 | ||||||||
Acquisition of Parallel 6 | 33,136 | — | 33,136 | ||||||||
Acquisition of TDC joint venture | 2,670 | — | 2,670 | ||||||||
Acquisition of TDS | 966 | — | 966 | ||||||||
Currency translation | 25,830 | — | 25,830 | ||||||||
Balance at September 30, 2017 | $ | 1,034,582 | $ | 500,475 | $ | 1,535,057 |
September 30, | December 31, | |||||||
2017 | 2016 | |||||||
Customer relationships | $ | 535,135 | $ | 360,328 | ||||
Customer backlog | 123,358 | 119,223 | ||||||
Trade names (definite-lived) | 28,457 | 25,740 | ||||||
Patient list, software and other intangibles | 55,574 | 28,974 | ||||||
Database | 64,600 | — | ||||||
Non-competition agreements | 2,767 | 2,737 | ||||||
Total finite-lived intangible assets, gross | 809,891 | 537,002 | ||||||
Accumulated amortization | (216,174 | ) | (181,036 | ) | ||||
Total finite-lived intangible assets, net | 593,717 | 355,966 | ||||||
Trade names (indefinite-lived) | 118,010 | 118,010 | ||||||
Total intangible assets, net | $ | 711,727 | $ | 473,976 |
2017 (remaining) | $ | 16,368 | |
2018 | 60,075 | ||
2019 | 54,375 | ||
2020 | 52,462 | ||
2021 | 50,331 | ||
2022 and thereafter | 360,106 | ||
Total | $ | 593,717 |
September 30, | December 31, | ||||||
2017 | 2016 | ||||||
Term loans, first lien | $ | 1,148,125 | $ | 625,000 | |||
Senior notes | 91,441 | 91,441 | |||||
Accounts receivable financing agreement | 120,000 | 120,000 | |||||
1,359,566 | 836,441 | ||||||
Less debt issuance costs and discount | (9,349 | ) | (8,139 | ) | |||
1,350,217 | 828,302 | ||||||
Less current portion | (56,719 | ) | (31,250 | ) | |||
Total long-term debt, net | $ | 1,293,498 | $ | 797,052 |
2017 (remaining) | $ | 11,250 | |
2018 | 60,625 | ||
2019 | 180,625 | ||
2020 | 76,250 | ||
2021 | 939,375 | ||
2022 and thereafter | 91,441 | ||
Total | $ | 1,359,566 |
• | $11.3 million per quarter, to be made commencing September 30, 2017 and made on or prior to December 31, 2017; |
• | $15.2 million per quarter, to be made on or after March 31, 2018, but on or prior to December 31, 2019; |
• | $19.1 million per quarter, to be made on or after March 31, 2020, but on or prior to December 31, 2020; |
• | $23.0 million per quarter, to be made on or after March 31, 2021, but prior to September 30, 2021; and |
• | the remaining principal amount of the term loan on December 6, 2021. |
2017 | 2016 | |||||||
Balance as of January 1, | $ | — | $ | — | ||||
Investment by noncontrolling interest | 5,440 | — | ||||||
Comprehensive income (loss) | ||||||||
Net income | 513 | — | ||||||
Foreign currency adjustments, net of income tax | (90 | ) | — | |||||
Balance as of September 30, | $ | 5,863 | $ | — |
Options | Wtd. Average Exercise Price | Wtd. Average Remaining Contractual Life (in years) | Intrinsic Value (millions) | ||||||||||
Outstanding at December 31, 2016 | 5,507,347 | $ | 15.38 | 6.7 | $ | 218.9 | |||||||
Granted | 1,831,000 | 74.93 | |||||||||||
Exercised | (1,758,846 | ) | 9.47 | ||||||||||
Expired or forfeited | (73,072 | ) | 26.94 | ||||||||||
Outstanding at September 30, 2017 | 5,506,429 | $ | 36.91 | 7.7 | $ | 216.2 | |||||||
Exercisable at September 30, 2017 | 2,557,710 | $ | 13.70 | 6.3 | $ | 159.8 |
Awards | Wtd. Average Grant-Date Fair Value | Intrinsic Value (millions) | |||||||||
Unvested at December 31, 2016 | 188,590 | $ | 32.63 | $ | 10.4 | ||||||
Granted | 131,044 | 63.05 | |||||||||
Forfeited | (2,000 | ) | 58.95 | ||||||||
Vested | (5,805 | ) | 38.81 | ||||||||
Unvested at September 30, 2017 | 311,829 | $ | 45.14 | $ | 23.8 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Direct costs | $ | 956 | $ | 438 | $ | 2,208 | $ | 1,319 | ||||||||
Selling, general and administrative | 2,493 | 1,228 | 5,478 | 3,621 | ||||||||||||
Transaction-related costs | 5,294 | — | 5,294 | 29,421 | ||||||||||||
Total stock-based compensation expense | $ | 8,743 | $ | 1,666 | $ | 12,980 | $ | 34,361 |
September 30, 2017 | December 31, 2016 | |||||||||||||||||
Balance Sheet Classification | Notional amount | Asset/ (Liability) | Notional amount | Asset/ (Liability) | ||||||||||||||
Derivatives in an asset position: | ||||||||||||||||||
Interest rate swap | Other assets | $ | 250,000 | $ | 73 | $ | — | $ | — | |||||||||
Derivatives in a liability position: | ||||||||||||||||||
Interest rate swap | Other long-term liabilities | $ | — | $ | — | $ | 250,000 | $ | (590 | ) |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
Derivatives in Cash Flow Hedging Relationships (Interest Rate Contracts) | 2017 | 2016 | 2017 | 2016 | ||||||||||||
Amount of pre-tax gain (loss) recognized in other comprehensive income (loss) on derivatives | $ | 35 | $ | 127 | $ | (32 | ) | $ | (2,546 | ) | ||||||
Amount of loss recognized in other income (expense), net on derivatives (ineffective portion) | — | — | — | — | ||||||||||||
Amount of loss reclassified from accumulated other comprehensive loss into interest expense, net on derivatives | (1,758 | ) | (1,617 | ) | (5,175 | ) | (4,242 | ) |
Foreign Currency Translation | Derivative Instruments, Net of Tax | Total | ||||||||||
Balance at December 31, 2016 | $ | (201,091 | ) | $ | (23,595 | ) | $ | (224,686 | ) | |||
Other comprehensive income before reclassifications | 75,167 | (21 | ) | 75,146 | ||||||||
Reclassification adjustments | — | 3,249 | 3,249 | |||||||||
Balance at September 30, 2017 | $ | (125,924 | ) | $ | (20,367 | ) | $ | (146,291 | ) |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||
Basic weighted average common shares outstanding | 62,730 | 60,937 | 62,185 | 60,579 | ||||||||
Effect of dilutive stock options and RSAs/RSUs | 3,142 | 3,584 | 3,498 | 3,689 | ||||||||
Diluted weighted average common shares outstanding | 65,872 | 64,521 | 65,683 | 64,268 | ||||||||
Anti-dilutive shares | 733 | 359 | 381 | 314 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Service revenue: | ||||||||||||||||
Clinical Research | $ | 475,588 | $ | 399,841 | $ | 1,360,610 | $ | 1,166,410 | ||||||||
Data Solutions | 18,962 | — | 18,962 | — | ||||||||||||
Total service revenue | 494,550 | 399,841 | 1,379,572 | 1,166,410 | ||||||||||||
Direct Costs: | ||||||||||||||||
Clinical Research | 314,904 | 259,910 | 903,027 | 758,333 | ||||||||||||
Data Solutions | 11,961 | — | 11,961 | — | ||||||||||||
Total direct costs | 326,865 | 259,910 | 914,988 | 758,333 | ||||||||||||
Gross Profit: | ||||||||||||||||
Clinical Research | 160,684 | 139,931 | 457,583 | 408,077 | ||||||||||||
Data Solutions | 7,001 | — | 7,001 | — | ||||||||||||
Total gross profit | $ | 167,685 | $ | 139,931 | $ | 464,584 | $ | 408,077 | ||||||||
Less expenses not allocated to segments: | ||||||||||||||||
Selling, general and administrative | 79,307 | 67,190 | 229,770 | 199,648 | ||||||||||||
Transaction-related costs | 12,740 | — | 12,740 | 31,785 | ||||||||||||
Depreciation and amortization | 18,853 | 17,708 | 50,146 | 52,246 | ||||||||||||
Loss on disposal of fixed assets, net | 8 | 219 | 240 | 290 | ||||||||||||
Consolidated income from operations | 56,777 | 54,814 | 171,688 | 124,108 | ||||||||||||
Interest expense, net | (11,557 | ) | (13,779 | ) | (31,088 | ) | (42,525 | ) | ||||||||
Loss on modification or extinguishment of debt | (3,089 | ) | — | (3,089 | ) | (21,485 | ) | |||||||||
Foreign currency (losses) gains, net | (12,794 | ) | 1,182 | (35,004 | ) | 9,264 | ||||||||||
Other income (expense), net | 1,004 | 20 | 724 | (85 | ) | |||||||||||
Consolidated income before income taxes and equity in income of unconsolidated joint ventures | $ | 30,341 | $ | 42,237 | $ | 103,231 | $ | 69,277 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||
U.S. dollars per: | ||||||||||||
Euro | 1.17 | 1.12 | 1.11 | 1.12 | ||||||||
British pound | 1.31 | 1.31 | 1.27 | 1.39 |
Three Months Ended September 30, | ||||||||
2017 | 2016 | |||||||
(in thousands) | ||||||||
Revenue | ||||||||
Service revenue | $ | 494,550 | $ | 399,841 | ||||
Reimbursement revenue | 87,459 | 53,414 | ||||||
Total revenue | 582,009 | 453,255 | ||||||
Operating expenses | ||||||||
Direct costs | 326,865 | 259,910 | ||||||
Reimbursable out-of-pocket costs | 87,459 | 53,414 | ||||||
Selling, general and administrative | 79,307 | 67,190 | ||||||
Transaction-related costs | 12,740 | — | ||||||
Depreciation and amortization | 18,853 | 17,708 | ||||||
Loss on disposal of fixed assets | 8 | 219 | ||||||
Income from operations | 56,777 | 54,814 | ||||||
Interest expense, net | (11,557 | ) | (13,779 | ) | ||||
Loss on modification of debt | (3,089 | ) | — | |||||
Foreign currency (losses) gains, net | (12,794 | ) | 1,182 | |||||
Other expense, net | 1,004 | 20 | ||||||
Income before income taxes and equity in income of unconsolidated joint ventures | 30,341 | 42,237 | ||||||
(Benefit from) provision for income taxes | (18,241 | ) | 10,821 | |||||
Income before equity in income of unconsolidated joint ventures | 48,582 | 31,416 | ||||||
Equity in income of unconsolidated joint ventures, net of tax | 24 | 33 | ||||||
Net income | 48,606 | 31,449 | ||||||
Net income attributable to noncontrolling interest | (401 | ) | — | |||||
Net income attributable to PRA Health Sciences, Inc. | $ | 48,205 | $ | 31,449 |
Nine Months Ended September 30, | ||||||||
2017 | 2016 | |||||||
(in thousands) | ||||||||
Revenue | ||||||||
Service revenue | $ | 1,379,572 | $ | 1,166,410 | ||||
Reimbursement revenue | 223,921 | 172,915 | ||||||
Total revenue | 1,603,493 | 1,339,325 | ||||||
Operating expenses | ||||||||
Direct costs | 914,988 | 758,333 | ||||||
Reimbursable out-of-pocket costs | 223,921 | 172,915 | ||||||
Selling, general and administrative | 229,770 | 199,648 | ||||||
Transaction-related costs | 12,740 | 31,785 | ||||||
Depreciation and amortization | 50,146 | 52,246 | ||||||
Loss on disposal of fixed assets | 240 | 290 | ||||||
Income from operations | 171,688 | 124,108 | ||||||
Interest expense, net | (31,088 | ) | (42,525 | ) | ||||
Loss on modification or extinguishment of debt | (3,089 | ) | (21,485 | ) | ||||
Foreign currency (losses) gains, net | (35,004 | ) | 9,264 | |||||
Other income (expense), net | 724 | (85 | ) | |||||
Income before income taxes and equity in income of unconsolidated joint ventures | 103,231 | 69,277 | ||||||
(Benefit from) provision for income taxes | (165 | ) | 17,869 | |||||
Income before equity in income of unconsolidated joint ventures | 103,396 | 51,408 | ||||||
Equity in income of unconsolidated joint ventures, net of tax | 92 | 2,742 | ||||||
Net income | 103,488 | 54,150 | ||||||
Net income attributable to noncontrolling interests | (513 | ) | — | |||||
Net income attributable to PRA Health Sciences, Inc. | $ | 102,975 | $ | 54,150 |
Three Months Ended September 30, | ||||||||||||
2017 | 2016 | Increase/(Decrease) | % Change | |||||||||
(in thousands) | ||||||||||||
Service Revenue | 475,588 | 399,841 | 75,747 | 18.9 | % | |||||||
Gross profit | 160,684 | 139,931 | 20,753 | 14.8 | % | |||||||
Gross profit % | 33.8 | % | 35.0 | % | (1.2 | )% |
Three Months Ended September 30, | |||||||||||
2017 | 2016 | Increase/(Decrease) | % Change | ||||||||
(in thousands) | |||||||||||
Service Revenue | 18,962 | — | 18,962 | n/a | |||||||
Gross profit | 7,001 | — | 7,001 | n/a | |||||||
Gross profit % | 36.9 | % | — | n/a |
Nine Months Ended September 30, | ||||||||||||
2017 | 2016 | Increase/(Decrease) | % Change | |||||||||
(in thousands) | ||||||||||||
Service Revenue | 1,360,610 | 1,166,410 | 194,200 | 16.6 | % | |||||||
Gross profit | 457,583 | 408,077 | 49,506 | 12.1 | % | |||||||
Gross profit % | 33.6 | % | 35.0 | % | (1.4 | )% |
Nine Months Ended September 30, | |||||||||||
2017 | 2016 | Increase/(Decrease) | % Change | ||||||||
(in thousands) | |||||||||||
Service Revenue | 18,962 | — | 18,962 | n/a | |||||||
Gross profit | 7,001 | — | 7,001 | n/a | |||||||
Gross profit % | 36.9 | % | — | n/a |
Payments Due by Period | ||||||||||||||||||||
Remaining 2017 (3 Months) | 2018 to 2019 | 2020 to 2021 | Thereafter | Total | ||||||||||||||||
Principal payments on long-term debt (1) | $ | 11,250 | $ | 241,250 | $ | 1,015,625 | $ | 91,441 | $ | 1,359,566 | ||||||||||
Interest payments on long-term debt (1) | 11,113 | 104,283 | 92,720 | 15,203 | 223,319 | |||||||||||||||
Contingent consideration on acquisition (2) | 67,789 | 50,775 | — | — | 118,564 | |||||||||||||||
Total | $ | 90,152 | $ | 396,308 | $ | 1,108,345 | $ | 106,644 | $ | 1,701,449 |
Exhibit | ||
Number | Description of Exhibit | |
101 | The following financial information from PRA Health Sciences, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 formatted in XBRL: (i) Consolidated Condensed Balance Sheets as of September 30, 2017 and December 31, 2016, (ii) Consolidated Condensed Statements of Operations for the three and nine months ended September 30, 2017 and 2016, (iii) Consolidated Condensed Statements of Comprehensive Income for the three and nine months ended September 30, 2017 and 2016, (iv) Consolidated Condensed Statements of Cash Flows for the nine months ended September 30, 2017 and 2016, and (v) Notes to Consolidated Condensed Financial Statements. |
* | Filed herewith |
PRA HEALTH SCIENCES, INC. | |
/s/ Linda Baddour | |
Linda Baddour | |
Executive Vice President and Chief Financial Officer | |
(Authorized Signatory) | |
Date: October 26, 2017 |
1. | I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2017 of PRA Health Sciences, Inc. (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date October 26, 2017 | |
/s/ Colin Shannon | |
Colin Shannon | |
President, Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) |
1. | I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2017 of PRA Health Sciences, Inc. (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date October 26, 2017 | |
/s/ Linda Baddour | |
Linda Baddour | |
Executive Vice President and Chief Financial Officer (Principal Financial Officer) |
Date October 26, 2017 | By: | /s/ Colin Shannon |
Colin Shannon | ||
President, Chief Executive Officer and Chairman of the Board of Directors | ||
(Principal Executive Officer) |
Date October 26, 2017 | By: | /s/ Linda Baddour |
Linda Baddour | ||
Executive Vice President and Chief Financial Officer | ||
(Principal Financial Officer) |
Document and Entity Information - shares |
9 Months Ended | |
---|---|---|
Sep. 30, 2017 |
Oct. 23, 2017 |
|
Document and Entity Information | ||
Entity Registrant Name | PRA Health Sciences, Inc. | |
Entity Central Index Key | 0001613859 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 63,369,729 | |
Document Fiscal Year Focus | 2017 | |
Document Fiscal Period Focus | Q3 |
CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 |
Common stock, shares issued (in shares) | 63,329,298 | 61,597,705 |
Common stock, shares outstanding (in shares) | 63,329,298 | 61,597,705 |
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 48,606 | $ 31,449 | $ 103,488 | $ 54,150 |
Other comprehensive income (loss): | ||||
Foreign currency translation adjustments | 26,863 | (11,211) | 75,076 | (55,548) |
Unrealized income (loss) on derivative instruments, net of income tax of $(11), $0, $(11) and $0 | 46 | 127 | (21) | (2,546) |
Reclassification adjustments: | ||||
(Gain) loss on derivatives included in net income, net of income taxes of $1,926, $0, $1,926 and $0 | (167) | 1,617 | 3,249 | 4,242 |
Comprehensive income | 75,348 | 21,982 | 181,792 | 298 |
Comprehensive income attributable to noncontrolling interest | (373) | 0 | (423) | 0 |
Comprehensive income attributable to PRA Health Sciences, Inc. | $ 74,975 | $ 21,982 | $ 181,369 | $ 298 |
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Statement of Comprehensive Income [Abstract] | ||||
Unrealized losses on derivative instruments, tax (benefit) | $ (11) | $ 0 | $ (11) | $ 0 |
Losses on derivatives included in net income, tax | $ 1,926 | $ 0 | $ 1,926 | $ 0 |
Basis of Presentation |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis of Presentation | Basis of Presentation The Company PRA Health Sciences, Inc. and its subsidiaries, or the Company, is a full-service global contract research organization providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. The Company’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. Unaudited Interim Financial Information The interim consolidated condensed financial statements include the accounts of the Company and variable interest entities where the Company is the primary beneficiary. These financial statements are prepared in conformity with U.S. generally accepted accounting principles, or GAAP, and are unaudited. In the opinion of the Company’s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The accompanying interim consolidated condensed financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. The preparation of the interim consolidated condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated condensed financial statements and the reported amounts of revenues and claims and expenses during the reporting period. Actual results could differ from those estimates. Variable Interest Entities A variable interest entity (“VIE”) is an entity in which a controlling financial interest may be achieved through arrangements that do not involve voting interests. A VIE is required to be consolidated by its primary beneficiary, which is the entity that possesses the power to direct the activities of the VIE that most significantly impact the VIEs economic performance and has the obligation to absorb losses or the right to receive benefits from the VIE that are significant to the entity. The Company consolidates VIEs when it is the primary beneficiary of the VIE, including joint ventures determined to be VIEs. For consolidated VIEs in which the Company owns less than 100% of the ownership interest or is exposed to less than 100% of the VIE’s economic performance, the outside stockholders' interests are shown as noncontrolling interests. Recently Implemented Accounting Pronouncements In March 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-09, “Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” This update includes provisions intended to simplify various aspects of accounting for share-based compensation. In addition, ASU No. 2016-09 went into effect for public companies for annual periods beginning after December 15, 2016. The Company adopted this ASU beginning with the first quarter of 2017. The adoption of this ASU had the following effects on the consolidated condensed financial statements: Income taxes - The standard requires excess tax benefits and tax deficiencies to be recorded as income tax benefit or expense in the statement of operations. The Company applied the modified retrospective adoption approach beginning in 2017 and recorded a cumulative-effect adjustment to retained earnings and reduced its deferred tax liabilities by $12.7 million with an offsetting increase to the valuation allowance of $12.7 million. As such, the net impact to retained earnings was zero. The Company continuously evaluates its need for a valuation allowance on its net deferred tax assets based upon the weight of available evidence. If the Company is able to support the recognition of certain net deferred tax assets in the future, it is noted that an additional tax benefit from the release of this additional valuation could occur at that time. This adjustment relates to tax assets that had previously arisen from tax deductions for equity compensation expenses that were greater than the compensation recognized for financial reporting. Forfeitures – The standard provides an accounting policy election to account for forfeitures as they occur. The Company made this accounting policy election and the modified retrospective adoption for this component of the standard did not have a material impact on its financial statements. Statements of Cash Flows - Cash flows related to excess tax benefits are no longer separately classified as a financing activity apart from other income tax cash flows. The Company adopted this component of the standard on a prospective basis. Earnings Per Share - The Company uses the treasury stock method to compute diluted earnings per share, unless the effect would be anti-dilutive. Under this method, the Company is no longer required to estimate the tax rate and apply it to the dilutive share calculation for determining the dilutive earnings per share. The Company adopted this component of the standard on a prospective basis. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows Classification of Certain Cash Receipts and Cash Payments,” which clarifies existing guidance related to accounting for cash receipts and cash payments and classification on the statement of cash flows. In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash,” which requires restricted cash be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted. The guidance for both standards requires application using a retrospective transition method. The Company early adopted both ASUs during the fourth quarter of 2016. As a result of the retrospective application of ASU No. 2016-15, $17.8 million of payments of debt prepayment and debt extinguishment costs originally recorded as operating cash outflows were reclassified to financing outflows in the consolidated condensed statement of cash flows for the nine months ended September 30, 2016. The retrospective application of ASU No. 2016-18 resulted in restricted cash being reclassified as a component of cash, cash equivalents, and restricted cash in the consolidated condensed statement of cash flows for all periods presented. Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers.” The new revenue standard establishes a single revenue recognition model for recognizing contracts from customers. Under the new standard, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The FASB has issued several amendments to the standard, including clarification on principal versus agent considerations, identifying performance obligations, and accounting for licenses of intellectual property. The new standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company plans to adopt the new revenue standard effective January 1, 2018 using the modified retrospective approach and continues to evaluate the potential impact to its consolidated financial statements. The Company’s implementation team consists of both internal resources and external advisors to assist with the adoption of the new standard. The Company completed a review of a representative sample of contracts from its contract portfolio and is continuing to evaluate key qualitative judgments associated with the adoption of the new revenue standard. The Company expects its long-term contracts currently accounted for using the proportional performance method may include additional contract value and costs used in the measure of progress as compared to its current accounting policies. The accounting for short-term contracts within the Clinical Research segment is expected to remain materially consistent with the current accounting treatment. The Company will complete its evaluation of the new standard in the fourth quarter, finalize its assessment of potential differences from its current accounting policies, and implement the necessary business processes, systems and controls required to support recognition and disclosure under the new standard. In February 2016, the FASB issued ASU No. 2016-02, “Leases,” which revises the accounting related to lessee accounting. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases with terms greater than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The provisions of ASU No. 2016-02 are effective for fiscal years beginning after December 15, 2018 and should be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. The Company is currently assessing the potential impact of ASU No. 2016-02 on the Company’s consolidated condensed financial statements. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations: Clarifying the Definition of a business,” which clarifies that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar identifiable assets, it should be treated as an acquisition or disposal of an asset. The amendments to ASU No. 2017-01 are effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of ASU No. 2017-01 is not expected to have a material impact on the Company's consolidated condensed financial statements. In January 2017, the FASB issued ASU No. 2017-04, “ Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment,” in order to simplify the subsequent measurement of goodwill by eliminating the Step 2 goodwill impairment test. Under the amendments in this ASU, an entity should perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity will then recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The amendments to ASU No. 2017-04 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The adoption of ASU No. 2017-04 is not expected to have a material impact on the Company's consolidated condensed financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation-Stock Compensation: Scope of Modification Accounting,” which provides guidance about what changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC Topic 718, “Stock Compensation.” The amendments to ASU No. 2017-09 are effective for reporting periods beginning after December 15, 2017, with early adoption permitted. The adoption of ASU No. 2017-09 is not expected to have a material impact on the Company's consolidated condensed financial statements. In August 2017, the FASB issued ASU No. 2017-12, "Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities," in order to simplify certain aspects of hedge accounting and improve disclosures of hedging arrangements. ASU No. 2017-12 eliminates the need to separately measure and report hedge ineffectiveness and generally requires the entire change in fair value of a hedging instrument to be presented in the same income statement line as the hedged item. Entities must apply the amendments to cash flow and net investment hedge relationships that exist on the date of adoption using a modified retrospective approach. The presentation and disclosure requirements must be applied prospectively. The amendments to ASU No. 2017-12 are effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The adoption of ASU No. 2017-12 is not expected to have a material impact on the Company's consolidated condensed financial statements. Restricted cash The Company receives cash advances from its customers to be used for the payment of investigator fees and other pass-through expenses. The terms of certain customer contracts require that such advances be maintained in separate escrow accounts; these accounts are not commingled with the Company’s cash and cash equivalents and are presented separately in the consolidated condensed balance sheets as restricted cash. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated condensed balance sheets that sum to the total of the same amounts shown in the consolidated condensed statements of cash flows:
Secondary Offerings In August 2017, KKR PRA Investors L.P., or KKR, and certain executive officers of the Company sold 10,000,000 shares of the Company’s common stock as part of a secondary offering, or the Secondary Offering. The Company incurred expenses in connection with the Secondary Offering of $1.0 million during the nine months ended September 30, 2017. The expenses are included in transaction-related costs in the accompanying consolidated condensed statement of operations. As of September 30, 2017, KKR owned 20.8% of the Company’s outstanding common stock. |
Business Combination |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations | Business Combinations Symphony Health Solutions, Inc. On September 6, 2017, the Company acquired all of the outstanding equity interest of Symphony Health Solutions Corporation, or Symphony Health, a provider of data and analytics to help professionals understand the full market lifecycle of products offered for sale by companies in the pharmaceutical industry, for $540.8 million in cash and contingent consideration, which is not capped, in the form of potential earn-out payments based on a multiple of future earnings for the twelve month periods ending December 2017 and December 2018. The Company recognized a liability of approximately $108.8 million representing the estimated fair value of the earn-out on the acquisition date, $90.4 million is included in accrued expenses and other current liabilities and $18.4 million is included in other long-term liabilities in the consolidated condensed balance sheet as of September 30, 2017. The fair value was based on significant inputs not observed in the market and thus represents a Level 3 measurement. Any change in the fair value of the contingent consideration subsequent to the acquisition date, excluding adjustments that qualify as measurement period adjustments, will be recognized in earnings in the period of any such change. With this acquisition, the Company expects to enhance its ability to serve customers throughout the clinical research process with technologies that provide data and analytics. The acquisition of Symphony Health was accounted for as a business combination and, accordingly, the assets acquired and the liabilities assumed have been recorded at their respective fair values as of the acquisition date. In connection with the acquisition, the Company recorded approximately $500.5 million of goodwill, which was assigned to the Data Solutions segment and is not deductible for income tax purposes. The goodwill is attributable to the workforce of the acquired business and expected synergies with the Company’s existing operations. The Company incurred $6.4 million in acquisition related costs that are included in transaction-related costs in the consolidated condensed statement of operations. Due to the timing of the acquisition, the valuation of net assets acquired has not been finalized and is expected to be completed by the end of December 2017, and in any case, no later than one year from the acquisition date in accordance with GAAP. The Company’s preliminary estimate of the purchase price allocation is as follows (in thousands):
The results of operations for Symphony Health are included in the consolidated condensed financial statements of the Company from the date of acquisition. During this period, Symphony Health's service revenues and net income totaled $19.0 million and $1.1 million, respectively. The following unaudited pro-forma information assumes the acquisition of Symphony Health occurred as of the beginning of 2016. This pro-forma financial information is not necessarily indicative of operating results if the acquisition had been completed at the date indicated, nor is it necessarily an indication of future operating results.
The unaudited pro-forma financial information for the nine months ended September 30, 2016 includes the following non-recurring adjustments:
Takeda Transactions On June 1, 2017, the Company acquired all of the outstanding shares of Takeda Pharmaceutical Data Services, Ltd., or TDS, from Takeda Pharmaceutical Company Ltd., or Takeda, for $0.7 million in cash. The Company recorded approximately $1.0 million of goodwill, which is assigned to the Clinical Research segment and is not deductible for income tax purposes. pro-forma results of operations and a complete purchase price allocation have not been presented because the results of this acquisition did not have a material effect on the Company's consolidated condensed financial statements. On June 1, 2017, the Company and Takeda also closed on a joint venture transaction that enables the Company to provide clinical trial delivery and pharmacovigilance services as a strategic partner of Takeda in Japan. The joint venture transaction was effected through the creation of a new legal entity, Takeda PRA Development Center KK, or TDC joint venture. The Company paid $5.4 million for a 50% equity interest in the TDC joint venture, which represents 50% of the fair value of the net assets and workforce that Takeda contributed to the joint venture. The joint venture provides services including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting, and medical monitoring. The Company is required to buy-out Takeda’s 50% interest in the TDC joint venture in two years. The Company also has an early buy-out option of Takeda’s 50% interest in December 2018 if both parties agree. The Company determined that the TDC joint venture is a VIE in which the Company is the primary beneficiary. Accordingly, the Company accounted for the $5.4 million contribution to the TDC joint venture as a business combination and consolidated the VIE in its financial statements with a noncontrolling interest for the 50% portion owned by Takeda. The assets acquired and the liabilities assumed have been recorded at their respective estimated fair values as of June 1, 2017. The Company recorded approximately $2.7 million of goodwill, which is assigned to the Clinical Research segment and is not deductible for income tax purposes. The goodwill is primarily attributable to assembled workforce. The Company incurred $0.6 million in acquisition related costs that are included in selling, general and administrative expenses in the consolidated condensed statement of operations. Due to the timing of the transaction, the valuation of net assets acquired has not been finalized and is expected to be completed by the end of December 2017, and in any case, no later than one year from the transaction closing date in accordance with GAAP. The Company’s preliminary estimate of the fair value of the net assets acquired as part of the TDC joint venture transaction at the closing date of the business combination is as follows (in thousands):
The Company has not disclosed post-acquisition or pro-forma revenue and earnings attributable to the TDC joint venture as they did not have a material effect on the Company’s consolidated condensed financial statements. Parallel 6, Inc. On May 10, 2017, the Company acquired all of the outstanding equity interest of Parallel 6, Inc., or Parallel 6, a developer of technologies for improving patient enrollment, engagement, and management of clinical trials, for $39.7 million in cash and contingent consideration in the form of a potential earn-out payment of up to $10.0 million. The earn-out payment is contingent upon the achievement of certain external software sales targets during the 18-month period following closing. The Company recognized a liability of approximately $8.4 million representing the estimated fair value of the earn-out on the acquisition date, which is included in other long-term liabilities in the consolidated condensed balance sheet as of September 30, 2017. The fair value was based on significant inputs not observed in the market and thus represented a Level 3 measurement. Any change in the fair value of the contingent consideration subsequent to the acquisition date, excluding adjustments that qualify as measurement period adjustments, will be recognized in earnings in the period of any such change. With this acquisition, the Company expects to enhance its ability to serve customers throughout the clinical research process with technologies that provide improved efficiencies by reducing study durations and costs through integrated operational management. The acquisition of Parallel 6 was accounted for as a business combination and, accordingly, the assets acquired and the liabilities assumed have been recorded at their respective fair values as of the acquisition date. In connection with the acquisition, the Company recorded approximately $33.1 million of goodwill, which was assigned to the Clinical Research segment and is not deductible for income tax purposes. The goodwill is attributable to the workforce of the acquired business and expected synergies with the Company’s existing information technology operations. The Company incurred $1.3 million in acquisition related costs that are included in selling, general and administrative expenses in the consolidated condensed statement of operations. Due to the timing of the acquisition, the valuation of net assets acquired has not been finalized and is expected to be completed by the end of December 2017, and in any case, no later than one year from the acquisition date in accordance with GAAP. The Company’s preliminary estimate of the purchase price allocation is as follows (in thousands):
The Company has not disclosed post-acquisition or pro-forma revenue and earnings attributable to Parallel 6 as they did not have a material effect on the Company’s consolidated condensed financial statements. Nextrials On March 18, 2016, the Company acquired all of the outstanding shares of Nextrials, Inc., or Nextrials, a developer of web-based software which integrates electronic health records with clinical trials, for $4.8 million in cash and contingent consideration in the form of potential earn-out payments of up to $3.0 million. Earn-out payments totaling $2.0 million and $1.0 million are contingent upon the achievement of project milestones and certain external software sales targets, respectively, during the 30-month period following closing. The Company recognized a liability of approximately $2.3 million as the estimated acquisition date fair value of the earn-out; the fair value was based on significant inputs not observed in the market and thus represented a Level 3 measurement. Changes in the fair value of the contingent consideration subsequent to the acquisition date are recognized in earnings in the period of the change. The fair value of the contingent consideration increased by $0.1 million for the nine months ended September 30, 2017. The Company made a payment of $0.4 million on the contingent consideration during the nine months ended September 30, 2017. As of September 30, 2017, the earn-out liability totaled $1.4 million; which is included in accrued expenses and other current liabilities in the consolidated condensed balance sheet. With this acquisition, the Company expects to enhance its ability to serve customers throughout the clinical research process with technologies that include improved efficiencies by reducing study durations and costs through integrated operational management. The acquisition of Nextrials was accounted for as a business combination and, accordingly, the assets acquired and the liabilities assumed have been recorded at their respective fair values as of the acquisition date. In connection with the acquisition, the Company recorded approximately $4.3 million of goodwill, which is assigned to the Clinical Research segment and is not deductible for income tax purposes. The goodwill is attributable to the workforce of the acquired business and expected synergies with the Company’s existing information technology operations. The Company’s purchase price allocation is as follows (in thousands):
The Company has not disclosed fiscal year 2016 or pro-forma revenue and earnings attributable to Nextrials as they did not have a material effect on the Company’s consolidated condensed financial statements. |
Fair Value Measurements |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:
The carrying amount of financial instruments, including cash and cash equivalents, accounts receivable, unbilled services, accounts payable and advanced billings, approximate fair value due to the short maturities of these instruments. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of September 30, 2017 (in thousands):
The Company's marketable securities are included in other current assets in the consolidated condensed balance sheet. These marketable securities are recorded at fair value using quoted prices in an active market. The interest rate swap is measured at fair value using a market approach valuation technique. The valuation is based on an estimate of net present value of the expected cash flows using relevant mid-market observable data inputs and based on the assumption of no unusual market conditions or forced liquidation. The Company values contingent consideration, related to business combinations, using a weighted probability of potential payment scenarios discounted at rates reflective of the weighted average cost of capital for the businesses acquired. Key assumptions used to estimate the fair value of contingent consideration include operational milestones and the probability of achieving the specific milestones The following table summarizes the changes in Level 3 financial liabilities measured on a recurring basis for the nine months ended September 30, 2017 (in thousands):
During the nine months ended September 30, 2017, the Company released the remaining $1.0 million contingent consideration liability associated with the acquisition of Value Health Solutions, Inc. as the earn-out targets were not met. Non-recurring Fair Value Measurements Certain assets and liabilities are carried on the accompanying consolidated condensed balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include finite-lived intangible assets which are tested when a triggering event occurs and goodwill and identifiable indefinite-lived intangible assets which are tested for impairment annually on October 1 or when a triggering event occurs. As of September 30, 2017, assets carried on the balance sheet and not remeasured to fair value on a recurring basis totaling approximately $2,246.8 million were identified as Level 3. These assets are comprised of goodwill of $1,535.1 million and identifiable intangible assets, net of $711.7 million. Refer to Note 7, Long-Term Debt, for additional information regarding the fair value of long-term debt balances. |
Concentration of Credit Risk |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Risks and Uncertainties [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, accounts receivable, and unbilled services. As of September 30, 2017, substantially all of the Company’s cash and cash equivalents were held in or invested with large financial institutions. Accounts receivable include amounts due from pharmaceutical and biotechnology companies. The Company establishes an allowance for potentially uncollectible receivables. In management’s opinion, there is no additional material credit risk beyond amounts provided for such losses. Service revenue from individual customers greater than 10% of consolidated service revenue in the respective periods was as follows:
Accounts receivable and unbilled receivables from individual customers that were equal to or greater than 10% of consolidated accounts receivable and unbilled receivables at the respective dates were as follows:
|
Accounts Receivable and Unbilled Services |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Receivables [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Receivable and Unbilled Services | Accounts Receivable and Unbilled Services Accounts receivable and unbilled services include service revenue, reimbursement revenue, and amounts associated with work performed by investigators. Accounts receivable and unbilled services were as follows (in thousands):
|
Goodwill and Intangible Assets |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets | Goodwill and Intangible Assets Goodwill The changes in the carrying amount of goodwill by reportable segment are as follows (in thousands):
There are no accumulated impairment charges as of September 30, 2017 and December 31, 2016. Intangible Assets Intangible assets consist of the following (in thousands):
Amortization expense was $11.3 million and $29.5 million for the three and nine months ended September 30, 2017, respectively, and $11.3 million and $34.3 million for the three and nine months ended September 30, 2016, respectively. The estimated future amortization expense of finite-lived intangible assets is expected to be as follows (in thousands):
The estimated fair value of the Early Development Services, or EDS, reporting unit closely approximated its carrying value when the Company performed its annual goodwill impairment test during the fourth quarter of 2014. The Company made operational improvements during 2015 and 2016 in order to improve the profitability of the EDS reporting unit. As a result of these changes, EDS saw growth in both backlog and new business awards that contributed to its improved financial performance during both years and led the Company to update its forecast for future periods. The Company considered all of these factors when it performed its most recent goodwill impairment test during the fourth quarter of 2016 and it was concluded that the estimated fair value of the EDS reporting unit exceeded its carrying value by approximately $70.0 million, or 33%. Any negative changes in assumptions on revenue, new business awards, cancellations, or the Company's ability to improve operations while maintaining a competitive cost structure could adversely affect the fair value of EDS and result in significant goodwill impairment charges in 2017 or later. |
Long-Term Debt |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-Term Debt | Long-Term Debt Long-term debt consists of the following (in thousands):
Principal payments on long-term debt are due as follows (in thousands):
2016 Credit Facilities As collateral for borrowings under the senior secured credit facilities, or 2016 Credit Facilities, the Company granted a pledge on primarily all of its assets, and the stock of wholly-owned U.S. restricted subsidiaries. The Company is subject to certain financial covenants, which require the Company to maintain certain debt-to-EBITDA and interest expense-to-EBITDA ratios. The 2016 Credit Facilities also contain covenants that, among other things, restrict the Company’s ability to create any liens, make investments and acquisitions, incur or guarantee additional indebtedness, enter into mergers or consolidations and other fundamental changes, conduct sales and other dispositions of property or assets, enter into sale-leaseback transactions or hedge agreements, prepay subordinated debt, pay dividends or make other payments in respect of capital stock, change the line of business, enter into transactions with affiliates, enter into burdensome agreements with negative pledge clauses and clauses restriction, and make subsidiary distributions. After giving effect to the applicable restrictions on the payment of dividends under the 2016 Credit Facilities, subject to compliance with applicable law, as of September 30, 2017 and December 31, 2016, all amounts in retained earnings were free of restriction and were available for the payment of dividends. The Company does not expect to pay dividends in the foreseeable future. The Company does not expect these covenants to restrict its liquidity, financial condition or access to capital resources in the foreseeable future. The 2016 Credit Facilities also contains customary representations, warranties, affirmative covenants, and events of default. On September 6, 2017, the Company borrowed $550.0 million under the 2016 Credit Facilities, or the Incremental Borrowing. The proceeds were primarily used to fund the acquisition of Symphony Health. In accordance with the guidance in FASB’s Accounting Standards Codification, or ASC, 470-50, "Debt - Modifications and Extinguishments," the Incremental Borrowing was accounted for as a debt modification. The Incremental Borrowing resulted in a $3.1 million loss on modification of debt, which consists of fees associated with the transaction for the nine months ended September 30, 2017. The 2016 Credit Facilities' first lien term loan's scheduled, fixed quarterly principal payments, including the Incremental Borrowing, are as follows:
The variable interest rate on the Incremental Borrowing is a rate equal to the London Interbank Offered Rate, or LIBOR, or the adjusted base rate, or ABR rate, at the election of the Company, plus a margin based on the ratio of total indebtedness to EBITDA and ranges from 1.00% to 2.00%, in the case of LIBOR rate loans, and 0.00% to 1.00%, in the case of ABR rate loans. There were no other changes to the 2016 Credit Facilities as a result of the Incremental Borrowing. For the nine months ended September 30, 2017, the weighted average interest rate on the first lien term loan was 3.45%. Revolving Credit Facilities The Company’s revolving credit facilities provide for $125.0 million of potential borrowings and expire on December 6, 2021. The interest rate on the revolving credit facilities is based on the LIBOR with a 0% LIBOR floor or ABR rate, at the election of the Company, plus an applicable margin, based on the leverage ratio of the Company. The Company, at its discretion, may elect interest periods of 1, 2, 3 or 6 months. The Company is required to pay to the lenders a commitment fee ranging from 0.2% to 0.4% based on the Company’s debt-to-EBITDA ratio. At September 30, 2017 and December 31, 2016, the Company had no outstanding borrowings under the revolving credit facilities. In addition, at September 30, 2017 and December 31, 2016, the Company had $4.5 million and $7.0 million, respectively, in letters of credit outstanding, which are secured by the revolving credit facilities. Senior Notes On March 17, 2016, the Company repaid $133.6 million aggregate principal amount of its 9.5% senior notes due 2023, or Senior Notes, as part of a cash tender offer. In accordance with the guidance in the ASC 470-50, "Debt—Modifications and Extinguishments," the debt repayment was accounted for as a partial debt extinguishment. The repayment resulted in a $21.5 million loss on extinguishment of debt, which consists of a $17.4 million early tender premium, a $3.7 million write-off of unamortized debt issuance costs and $0.4 million of fees associated with the transaction for the nine months ended September 30, 2016. The Senior Notes agreement contains certain provisions that restrict the payment of dividends from the Company’s subsidiaries to the parent company. As a result, there are no material balances present within the parent company that are available for the payment of dividends as the parent company did not have any net income during 2016 or the nine months ended September 30, 2017, that was free of restrictions. The Company does not expect to pay dividends in the foreseeable future. Accounts Receivable Financing Agreement In March 2016, the Company entered into a $140.0 million accounts receivable financing agreement, of which $120.0 million was outstanding as of September 30, 2017 and December 31, 2016. The borrowings were used to repay amounts outstanding on the Company’s revolving credit facility that were used to fund the cash tender offer for the Senior Notes. Loans under the accounts receivable financing agreement accrue interest at either a reserve-adjusted LIBOR or a base rate, plus 1.6%. The Company may prepay loans upon one business day prior notice and may terminate the accounts receivable financing agreement with 15 days’ prior notice. For the nine months ended September 30, 2017, the weighted average interest rate on the accounts receivable financing agreement was 2.91%. The accounts receivable financing agreement contains various customary representations and warranties and covenants, and default provisions which provide for the termination and acceleration of the commitments and loans under the agreement in circumstances including, but not limited to, failure to make payments when due, breach of representations, warranties or covenants, certain insolvency events or failure to maintain the security interest in the trade receivables, and defaults under other material indebtedness. The accounts receivable financing agreement terminates on March 22, 2019, unless terminated earlier pursuant to its terms. At September 30, 2017 and December 31, 2016, there was $20.0 million of remaining capacity available under the accounts receivable financing agreement. Fair Value of Debt The estimated fair value of the Company’s debt was $1,368.8 million and $844.2 million at September 30, 2017 and December 31, 2016, respectively. The fair value of the Senior Notes, which totaled $100.7 million and $99.2 million at September 30, 2017 and December 31, 2016, respectively, was determined based on Level 2 inputs using the market approach, which is primarily based on rates at which the debt is traded among financial institutions. The fair value of the term loans, borrowings under credit facilities, and accounts receivable financing agreement which totaled $1,268.1 million and $745.0 million at September 30, 2017 and December 31, 2016, respectively, was determined based on Level 3 inputs, which is primarily based on rates at which the debt is traded among financial institutions adjusted for the Company's credit standing. |
Stockholders' Equity |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity | Stockholders’ Equity Authorized Shares The Company is authorized to issue up to one billion shares of common stock, with a par value of $0.01. The Company is authorized to issue up to one hundred million shares of preferred stock, with a par value of $0.01. Noncontrolling Interest Below is a summary of noncontrolling interest for the nine months ended September 30 (in thousands):
|
Stock-Based Compensation |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-Based Compensation | Stock-Based Compensation The Company granted 1,831,000 service-based options and 131,044 restricted stock awards and units, or RSAs/RSUs, with a total grant date fair value of $46.0 million and $8.3 million, respectively, during the nine months ended September 30, 2017. Aggregated information regarding the Company’s option plans is summarized below:
The Company’s RSAs/RSUs activity in 2017 is as follows:
Stock-based compensation expense related to employee stock options and RSAs/RSUs is summarized below (in thousands):
All stock options granted under the 2013 Stock Incentive Plan for Key Employees of PRA Health Sciences, Inc. and its Subsidiaries, or the Plan, are subject to transfer restrictions of the stock option's underlying shares once vested and exercised. This lack of marketability was included as a discount when calculating the grant date value of these options. In conjunction with secondary offerings, the transfer restrictions on a portion of such shares issuable upon exercise of vested options granted under the Plan were released. The release of the transfer restrictions is considered a modification under ASC Topic 718, “Stock Compensation.” As a result of these modifications, the Company incurred approximately $5.3 million and $4.9 million of incremental compensation expense associated with service-based options during the nine months ended September 30, 2017 and September 30, 2016, respectively, which is included in transaction-related costs in the accompanying consolidated condensed statement of operations. In December 2013, the Company granted certain employees market-based options under the Plan that vest only upon the achievement of a specified internal rate of return from a liquidity event (“2.0x Options”). At the time of grant, no compensation expense was recorded as the 2.0x Options vest upon a liquidity event, which is not considered probable until the date it occurs. On January 20, 2016, the Compensation Committee of the Board of Directors adopted a resolution to adjust the vesting criteria for all 2.0x Options granted and still outstanding on such date. Under the revised vesting criteria, the 2.0x Options vest upon the announcement of a secondary offering. This modification resulted in Type IV Improbable-to-Improbable modification. Since the secondary offering was deemed improbable due to the fact that it is outside of the Company’s control and cannot be considered probable until the date it occurs, no compensation expense was recognized on the January 20, 2016 modification date. On March 2, 2016, the Company announced a secondary offering of shares by KKR and certain management stockholders, and it became probable that the 2.0x Options would vest. In total, 835,551 2.0x Options held by current employees were modified. As a result of this modification, and the modification associated with the transfer restrictions releases noted above, the Company incurred approximately $24.5 million of incremental compensation expense associated with the 2.0x Options during the nine months ended September 30, 2016, which is included in transaction-related costs in the accompanying consolidated condensed statement of operations. Employee Stock Purchase Plan In April 2017, the Board of Directors approved the PRA Health Sciences, Inc. 2017 Employee Stock Purchase Plan (“ESPP”) which was approved by the Company’s shareholders on June 1, 2017. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary or wages to be applied toward the purchase of shares of the Company’s common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to 15% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in six month increments, commencing on January 1 and July 1 of each calendar year with the compensation committee having the right to establish different offering periods. |
Income Taxes |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The Company’s effective income tax rate was (0.2)% and 25.8% for the nine months ended September 30, 2017 and 2016, respectively. The variation between the Company’s effective income tax rate and the U.S. statutory rate of 35% for the nine months ended September 30, 2017 is primarily due to (i) the benefit realized from the tax deduction of stock awards in excess of the amount recognized in the financial statements per the guidance under ASU No. 2016-09, and (ii) the release of the valuation allowance against the Company's federal net deferred tax assets as a result of the acquisition of Symphony Health. GAAP requires a two-step approach when evaluating uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence demonstrates that it is more likely than not that the position will be sustained upon audit, including resolution of any related appeals or litigation processes. The second step is to quantify the amount of tax benefit to recognize as the amount that is cumulatively more than 50% likely to be realized upon ultimate settlement with the taxing authorities. As of September 30, 2017, the Company’s liability for unrecognized tax benefits was $13.0 million. If any portion of this $13.0 million is recognized that impacts the effective tax rate, the Company will then include that portion in the computation of its effective tax rate. Although the ultimate timing of the resolution of audits is highly uncertain, the Company believes it is reasonably possible that approximately $4.5 million of gross unrecognized tax benefits will change in the next 12 months as a result of pending audit settlements or statute of limitations expirations. The Company files federal, state, and foreign tax returns. For federal purposes, the Company is generally no longer subject to tax examinations for years ended December 31, 2013 and prior. For state tax returns, the Company is generally no longer subject to tax examinations for years prior to 2012. For foreign purposes, the Company is generally no longer subject to examination for tax periods 2009 and prior. Certain carryforward tax attributes generated in prior years remain subject to examination and adjustment. |
Commitments and Contingencies |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Proceedings The Company is involved in legal proceedings from time to time in the ordinary course of its business, including employment claims and claims related to other business transactions. Although the outcome of such claims is uncertain, management believes that these legal proceedings will not have a material adverse effect on the financial condition or results of future operations of the Company. The Company is currently a party to litigation with the City of Sao Paulo, Brazil. The dispute relates to whether the export of services provided by the Company is subject to a local tax on services. The Company has not recorded a liability associated with the claim, which totaled $5.4 million at September 30, 2017, given that it is not deemed probable the Company will incur a loss related to this case. However, a deposit totaling $5.4 million has been made to the Brazilian court in order to annul the potential tax obligation and to avoid the accrual of additional interest and penalties. This balance is recorded in other assets on the consolidated condensed balance sheet. In June 2015, the Judiciary Court of Justice of the State of Sao Paulo ruled in the favor of the Company, however, the judgment was appealed by the City of Sao Paulo. The Company expects to recover the full amount of the deposit when the case is settled. In September 2017, a judge from the Superior Court of Justice of Brazil denied relief to the City of Sao Paulo's appeal and upheld the lower court's ruling in the favor of the Company for the years 2011, 2012, and in the period from January to October 2013. The judge from the Superior Court of Justice of Brazil also ruled that the Company must appeal the lower court's verdict for the period November 2013 through September 2017 as the Judiciary Court of Justice of the State of Sao Paulo only reviewed the facts that pertained to the period before November 2013. |
Derivatives |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivatives | Derivatives The Company is exposed to certain risks relating to its ongoing business operations. The primary risk that the Company seeks to manage by using derivative instruments is interest rate risk. Accordingly, the Company has instituted interest rate hedging programs that are accounted for in accordance with ASC 815, “Derivatives and Hedging.” The interest rate hedging program is a cash flow hedge program designed to minimize interest rate volatility. The Company swaps the difference between fixed and variable interest amounts calculated by reference to an agreed-upon notional principal amount, at specified intervals. The Company’s interest rate contracts are designated as hedging instruments. The following table presents the notional amounts and fair values (determined using Level 2 inputs) of the Company’s derivatives as of September 30, 2017 and December 31, 2016 (in thousands):
The Company records the effective portion of any change in the fair value of derivatives designated as hedging instruments under ASC 815 to other accumulated comprehensive loss in the Company's consolidated condensed balance sheet, net of deferred taxes, and will later reclassify into earnings when the hedged item affects earnings or is no longer expected to occur. Gains and losses from the ineffective portion of any hedge are recognized in earnings immediately. For other derivative contracts that do not qualify or no longer qualify for hedge accounting, changes in the fair value of the derivatives are recognized in earnings each period. The table below presents the effect of the Company's derivatives on the consolidated condensed statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2017 and 2016 (in thousands):
The Company expects that $6.6 million of unrealized losses will be reclassified out of accumulated other comprehensive loss and into interest expense, net over the next 12 months. |
Accumulated Other Comprehensive Loss |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Loss | Accumulated Other Comprehensive Loss Below is a summary of the components of accumulated other comprehensive loss (in thousands):
The change in the Company's foreign currency translation adjustment was due primarily to the movements in the British pound and Euro exchange rates against the U.S. dollar. The U.S. dollar weakened by 8.6% and 12.0% versus the British pound and Euro, respectively, between December 31, 2016 and September 30, 2017. The movement in the British pound and Euro represented $42.1 million and $26.8 million, respectively, out of the $75.2 million foreign currency translation adjustment during the nine months ended September 30, 2017. The remaining foreign currency translation adjustment is primarily attributable to the U.S. dollar’s depreciation against other major world-wide currencies, including the Canadian dollar and the Russian ruble. |
Net Income Per Share |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income Per Share | Net Income Per Share Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding for the applicable period. Diluted net income per share is calculated after adjusting the denominator of the basic net income per share calculation for the effect of all potentially dilutive common shares, which, in the Company’s case, includes shares issuable under the stock option and incentive award plan. The following table reconciles the basic to diluted weighted average shares outstanding (in thousands):
The anti-dilutive shares disclosed above were calculated using the treasury stock method. The treasury stock method calculates dilution assuming the exercise of all in-the-money options and vesting of RSAs/RSUs, reduced by the repurchase of shares with the proceeds from the assumed exercises, and unrecognized compensation expense for outstanding awards. |
Segments |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segments | Segments In conjunction with the acquisition of Symphony Health on September 6, 2017, the Company expanded its reporting segments. The Company is now managed through two reportable segments, Clinical Research and Data Solutions. Clinical Research, which primarily serves biopharmaceutical clients, provides outsourced clinical research and clinical trial related services. Data Solutions provides mission critical information, technology solutions and real-world insights and services to the Company’s life science clients. Reimbursement revenue and reimbursable out-of-pocket costs are not presented, as this measure is not used by the chief operating decision maker to assess the Company's performance. The Company’s reportable segment information is presented below (in thousands):
|
Basis of Presentation (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of cash, cash equivalents, and restricted cash | The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated condensed balance sheets that sum to the total of the same amounts shown in the consolidated condensed statements of cash flows:
|
Business Combination (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Symphony Health Solutions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of purchase price allocation | The Company’s preliminary estimate of the purchase price allocation is as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of unudited pro-forma information | The following unaudited pro-forma information assumes the acquisition of Symphony Health occurred as of the beginning of 2016. This pro-forma financial information is not necessarily indicative of operating results if the acquisition had been completed at the date indicated, nor is it necessarily an indication of future operating results.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition of TDC joint venture | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of purchase price allocation | The Company’s preliminary estimate of the fair value of the net assets acquired as part of the TDC joint venture transaction at the closing date of the business combination is as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Parallel 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of purchase price allocation | The Company’s preliminary estimate of the purchase price allocation is as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nextrials | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of purchase price allocation | The Company’s purchase price allocation is as follows (in thousands):
|
Fair Value Measurements (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of the fair value of financial assets and liabilities measured on a recurring basis | The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of September 30, 2017 (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of the changes in Level 3 financial assets and liabilities measured on a recurring basis | The following table summarizes the changes in Level 3 financial liabilities measured on a recurring basis for the nine months ended September 30, 2017 (in thousands):
|
Concentration of Credit Risk (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Service revenue | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration risk | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of concentration of risk by risk factor | Service revenue from individual customers greater than 10% of consolidated service revenue in the respective periods was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts receivable and unbilled receivables | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Concentration risk | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of concentration of risk by risk factor | Accounts receivable and unbilled receivables from individual customers that were equal to or greater than 10% of consolidated accounts receivable and unbilled receivables at the respective dates were as follows:
|
Accounts Receivable and Unbilled Services (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Receivables [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of accounts receivable and unbilled services | Accounts receivable and unbilled services include service revenue, reimbursement revenue, and amounts associated with work performed by investigators. Accounts receivable and unbilled services were as follows (in thousands):
|
Goodwill and Intangible Assets (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of changes in the carrying amount of goodwill | The changes in the carrying amount of goodwill by reportable segment are as follows (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of intangible assets | Intangible assets consist of the following (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of estimated future amortization expense | The estimated future amortization expense of finite-lived intangible assets is expected to be as follows (in thousands):
|
Long-Term Debt (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of long-term debt | Long-term debt consists of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of principal payments on long-term debt due | Principal payments on long-term debt are due as follows (in thousands):
|
Stockholders' Equity (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of noncontrolling interest | Below is a summary of noncontrolling interest for the nine months ended September 30 (in thousands):
|
Stock-Based Compensation (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of stock option activity | Aggregated information regarding the Company’s option plans is summarized below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of RSA/RSU activity | The Company’s RSAs/RSUs activity in 2017 is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of stock-based compensation expense | Stock-based compensation expense related to employee stock options and RSAs/RSUs is summarized below (in thousands):
|
Derivatives (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of notional amounts and fair values (determined using level 2 inputs) of derivatives | The following table presents the notional amounts and fair values (determined using Level 2 inputs) of the Company’s derivatives as of September 30, 2017 and December 31, 2016 (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of the effect of derivatives on the condensed consolidated statements of operations and comprehensive (loss) income | The table below presents the effect of the Company's derivatives on the consolidated condensed statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2017 and 2016 (in thousands):
|
Accumulated Other Comprehensive Loss (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of components of accumulated other comprehensive loss | Below is a summary of the components of accumulated other comprehensive loss (in thousands):
|
Net Income Per Share (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of weighted average basic and diluted common shares | The following table reconciles the basic to diluted weighted average shares outstanding (in thousands):
|
Segments (Tables) |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Segment Reporting Information | The Company’s reportable segment information is presented below (in thousands):
|
Basis of Presentation - Recently Implemented Accounting Pronouncements (Details) - USD ($) |
9 Months Ended | |||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Jan. 01, 2017 |
Dec. 31, 2016 |
|
Recently Implemented Accounting Pronouncements | ||||
Deferred tax liabilities | $ (128,366,000) | $ (73,703,000) | ||
Operating cash flows | (117,828,000) | $ (66,708,000) | ||
Financing cash outflows | 523,670,000 | $ (30,745,000) | ||
Accounting Standards Update 2016-09 | ||||
Recently Implemented Accounting Pronouncements | ||||
Deferred tax liabilities | $ 12,700,000 | |||
Valuation allowance | 12,700,000 | |||
Accounting Standards Update 2016-09 | Retained Earnings | ||||
Recently Implemented Accounting Pronouncements | ||||
Retained earnings | $ 0 | |||
Accounting Standards Update 2016-15 | Effect of early adoption of ASU | ||||
Recently Implemented Accounting Pronouncements | ||||
Operating cash flows | 17,800,000 | |||
Financing cash outflows | $ 17,800,000 |
Basis of Presentation - Restricted Cash (Details) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
Sep. 30, 2016 |
Dec. 31, 2015 |
---|---|---|---|---|
Cash, cash equivalents, and restricted cash | ||||
Cash and cash equivalents | $ 193,581 | $ 144,623 | $ 130,343 | $ 121,065 |
Restricted cash | 697 | 4,715 | 5,235 | 5,060 |
Total cash, cash equivalents, and restricted cash | $ 194,278 | $ 149,338 | $ 135,578 | $ 126,125 |
Basis of Presentation Basis of Presentation - Secondary Offerings (Details) - USD ($) $ in Millions |
1 Months Ended | 9 Months Ended |
---|---|---|
Aug. 31, 2017 |
Sep. 30, 2017 |
|
Subsidiary, Sale of Stock [Line Items] | ||
KKR ownership of the Company's outstanding common stock (as a percentage) | 20.80% | |
Secondary stock offering | ||
Subsidiary, Sale of Stock [Line Items] | ||
Shares sold in secondary offering (in shares) | 10,000,000 | |
Secondary stock offering - shares from existing shareholders (in shares) | ||
Subsidiary, Sale of Stock [Line Items] | ||
Professional fees for secondary offering | $ 1.0 |
Business Combination - Preliminary Estimate of the Purchase Price Allocation - SHS (Details) - Acquisition of Symphony Health $ in Thousands |
Sep. 06, 2017
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Cash and cash equivalents | $ 26,297 |
Accounts receivable | 39,056 |
Other current assets | 24,048 |
Fixed assets | 12,340 |
Accounts payable and accrued expenses | (42,700) |
Deferred revenue | (65,511) |
Deferred tax liabilities | (75,056) |
Other long-term liabilities | (7,940) |
Estimated fair value of net assets acquired | 149,134 |
Purchase price, including contingent consideration | 649,609 |
Total goodwill | 500,475 |
Software intangible | |
Business Acquisition [Line Items] | |
Software intangible | $ 13,000 |
Weighted Amortization Period | 5 years |
Database | |
Business Acquisition [Line Items] | |
Software intangible | $ 64,600 |
Weighted Amortization Period | 9 years |
Customer relationships | |
Business Acquisition [Line Items] | |
Software intangible | $ 161,000 |
Weighted Amortization Period | 12 years |
Business Combination - Unaudited Pro-Forma Information (Details) - Symphony Health Solutions - USD ($) $ / shares in Units, $ in Thousands |
9 Months Ended | |
---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Business Acquisition [Line Items] | ||
Acquisition-related revenue | $ 1,752,514 | $ 1,484,013 |
Net income attributable to PRA Health Sciences, Inc. | $ 126,092 | $ 35,830 |
Net income per share, basic (in dollars per share) | $ 2.03 | $ 0.59 |
Net income per share, diluted (in dollars per share) | $ 1.92 | $ 0.56 |
Business Combination - Preliminary Estimate of Net Assets Acquired TDC Joint Venture (Details) - Acquisition of TDC joint venture $ in Thousands |
Jun. 01, 2017
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Cash and cash equivalents | $ 8,120 |
Other current assets | 1,671 |
Other non-current assets | 1,742 |
Accounts payable and accrued expenses | (2,380) |
Other long-term liabilities | (943) |
Estimated fair value of net assets acquired | 8,210 |
Purchase price, including contingent consideration | 5,440 |
Fair value of Takeda's noncontrolling interest | 5,440 |
Total goodwill | $ 2,670 |
Business Combination - Preliminary Estimate of the Purchase Price Allocation (Details) - Parallel 6 $ in Thousands |
May 10, 2017
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Cash and cash equivalents | $ 132 |
Accounts receivable | 1,231 |
Other current assets | 26 |
Accounts payable and accrued expenses | (885) |
Deferred revenue | (994) |
Other long-term liabilities | (2,414) |
Estimated fair value of net assets acquired | 13,516 |
Purchase price, including contingent consideration | 46,652 |
Software intangible | |
Business Acquisition [Line Items] | |
Software intangible | $ 15,500 |
Weighted Amortization Period | 5 years |
Other intangibles | |
Business Acquisition [Line Items] | |
Software intangible | $ 920 |
Weighted Amortization Period | 5 years |
Clinical Research | |
Business Acquisition [Line Items] | |
Total goodwill | $ 33,100 |
Business Combination - Company's Purchase Price Allocation (Details) - Nextrials $ in Thousands |
Mar. 18, 2016
USD ($)
|
---|---|
Business Acquisition [Line Items] | |
Cash and cash equivalents | $ 94 |
Accounts receivable | 211 |
Other current assets | 96 |
Property, plant and equipment | 111 |
Accounts payable and accrued expenses | (1,585) |
Other long-term liabilities | (1,663) |
Estimated fair value of net assets acquired | 2,838 |
Purchase price, including contingent consideration | 7,145 |
Software intangible | |
Business Acquisition [Line Items] | |
Software intangible | $ 5,574 |
Weighted Amortization Period | 5 years |
Clinical Research | |
Business Acquisition [Line Items] | |
Total goodwill | $ 4,307 |
Fair Value Measurements - Non-recurring Fair Value Measurements (Details) - Nonrecurring - Level 3 $ in Millions |
Sep. 30, 2017
USD ($)
|
---|---|
Assets fair value measurements | |
Assets fair value | $ 2,246.8 |
Goodwill | 1,535.1 |
Identifiable intangible assets | $ 711.7 |
Concentration of Credit Risk (Details) - Customer Concentration Risk |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
---|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Dec. 31, 2016 |
|
Service revenue | Customer A | |||||
Concentration risk | |||||
Concentration risk percentage | 10.10% | 11.70% | 10.60% | 10.80% | |
Service revenue | Customer B | |||||
Concentration risk | |||||
Concentration risk percentage | 0.00% | 10.40% | 0.00% | 10.70% | |
Service revenue | Customer C | |||||
Concentration risk | |||||
Concentration risk percentage | 0.00% | 10.20% | 0.00% | 0.00% | |
Accounts receivable and unbilled receivables | Customer A | |||||
Concentration risk | |||||
Concentration risk percentage | 10.70% | 12.00% |
Accounts Receivable and Unbilled Services (Details) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Receivables [Abstract] | ||
Accounts receivable | $ 457,306 | $ 284,647 |
Unbilled services | 172,152 | 155,609 |
Total accounts receivable, gross | 629,458 | 440,256 |
Less allowance for doubtful accounts | (1,429) | (1,203) |
Total accounts receivable and unbilled services, net | $ 628,029 | $ 439,053 |
Goodwill and Intangible Assets - Narrative (Details) - USD ($) |
3 Months Ended | 9 Months Ended | ||||
---|---|---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
Jun. 30, 2017 |
Dec. 31, 2016 |
|
Finite-Lived Intangible Assets [Line Items] | ||||||
Amortization expense | $ 11,300,000 | $ 11,300,000 | $ 29,500,000 | $ 34,300,000 | ||
Accumulated impairment charges | $ 0 | $ 0 | ||||
EDS | ||||||
Finite-Lived Intangible Assets [Line Items] | ||||||
Fair value of reporting unit in excess of carrying amount | $ 70,000,000 | |||||
Percent of fair value of reporting unit in excess of carrying amount | 33.00% |
Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] | ||
2017 (remaining) | $ 16,368 | |
2018 | 60,075 | |
2019 | 54,375 | |
2020 | 52,462 | |
2021 | 50,331 | |
2022 and thereafter | 360,106 | |
Total finite-lived intangible assets, net | $ 593,717 | $ 355,966 |
Long-Term Debt - Summary (Details) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Long-term debt | ||
Long-term debt, gross | $ 1,359,566 | $ 836,441 |
Less debt issuance costs and discount | (9,349) | (8,139) |
Total | 1,350,217 | 828,302 |
Less current portion | (56,719) | (31,250) |
Total long-term debt, net | 1,293,498 | 797,052 |
Term loans, first lien | ||
Long-term debt | ||
Long-term debt, gross | 1,148,125 | 625,000 |
Senior notes | ||
Long-term debt | ||
Long-term debt, gross | 91,441 | 91,441 |
Accounts receivable financing agreement | ||
Long-term debt | ||
Long-term debt, gross | $ 120,000 | $ 120,000 |
Long-Term Debt - Future Principal Payments (Details) - USD ($) $ in Thousands |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Principal payments on long-term debt | ||
2017 (remaining) | $ 11,250 | |
2018 | 60,625 | |
2019 | 180,625 | |
2020 | 76,250 | |
2021 | 939,375 | |
2022 and thereafter | 91,441 | |
Total | $ 1,359,566 | $ 836,441 |
Stockholders' Equity (Details) - $ / shares |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Stockholders' Equity Note [Abstract] | ||
Common stock, shares authorized (in shares) | 1,000,000,000 | 1,000,000,000 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Stockholders' Equity - Noncontrolling Interest (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Summary of noncontrolling interest | ||||
Balance as of January 1, | $ 0 | $ 0 | ||
Investment by noncontrolling interest | 5,440 | 0 | ||
Comprehensive income (loss) | ||||
Net income | $ 401 | $ 0 | 513 | 0 |
Foreign currency adjustments, net of income tax | (90) | 0 | ||
September 30, | $ 5,863 | $ 0 | $ 5,863 | $ 0 |
Stock-Based Compensation - Restricted Stock Awards and Units (Details) - RSAs and RSUs - USD ($) $ / shares in Units, $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2017 |
Dec. 31, 2016 |
|
Awards | ||
Outstanding at beginning of period (in shares) | 188,590 | |
Granted (in shares) | 131,044 | |
Forfeited (in shares) | (2,000) | |
Vested (in shares) | (5,805) | |
Outstanding at end of period (in shares) | 311,829 | |
Wtd. Average Grant-Date Fair Value | ||
Outstanding at beginning of period (in dollars per share) | $ 32.63 | |
Granted (in dollars per share) | 63.05 | |
Forfeited (in dollars per share) | 58.95 | |
Vested (in dollars per share) | 38.81 | |
Outstanding at end of period (in dollars per share) | $ 45.14 | |
Intrinsic Value | ||
Outstanding at end of period | $ 23.8 | $ 10.4 |
Stock-Based Compensation - Employee Stock Purchase Plan (Details) - 2017 Employee Stock Purchase Plan |
9 Months Ended |
---|---|
Sep. 30, 2017 | |
Employee Stock Purchase Plan | |
Offering period increments under the ESPP | 6 months |
Maximum | |
Employee Stock Purchase Plan | |
Payroll deduction, as a percentage of base wages, an employee may authorize to be applied toward the purchase of common stock under the ESPP | 10.00% |
Percentage of discount on the purchase price of common stock during the offering period under the ESPP | 15.00% |
Income Taxes (Details) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Income Tax Disclosure [Abstract] | ||
Effective income tax rate (as a percent) | (0.20%) | 25.80% |
U.S. statutory rate (as a percent) | 35.00% | |
Liability for unrecognized tax benefits | $ 13.0 | |
Amount of gross unrecognized tax benefits that will change in the next 12 months as a result of pending audit settlements or statute of limitations expirations | $ 4.5 |
Commitments and Contingencies (Details) - Tax related claim on export of services provided $ in Millions |
Sep. 30, 2017
USD ($)
|
---|---|
Commitments and Contingencies | |
Amount of tax claimed to be due in litigation | $ 5.4 |
Other assets | |
Commitments and Contingencies | |
Deposit made to Brazilian court in tax litigation | $ 5.4 |
Derivatives - Hedging Instruments (Details) - Interest rate swap - Designated as hedging instruments - Level 2 - USD ($) |
Sep. 30, 2017 |
Dec. 31, 2016 |
---|---|---|
Other assets | ||
Derivatives in an asset position: | ||
Notional amount | $ 250,000,000 | $ 0 |
Asset/ (Liability) | 73,000 | 0 |
Other long-term liabilities | ||
Derivatives in a liability position: | ||
Notional amount | 0 | 250,000,000 |
Asset/ (Liability) | $ 0 | $ (590,000) |
Derivatives - Cash Flow Hedging Instruments (Details) - Cash flow hedging - Interest rate contracts - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Effect of derivatives on the consolidated statements of operations and comprehensive income (loss) | ||||
Amount of pre-tax gain (loss) recognized in other comprehensive income (loss) on derivatives | $ 35,000 | $ 127,000 | $ (32,000) | $ (2,546,000) |
Amount of loss recognized in other income (expense), net on derivatives (ineffective portion) | 0 | 0 | 0 | 0 |
Amount of loss reclassified from accumulated other comprehensive loss into interest expense, net on derivatives | $ (1,758,000) | $ (1,617,000) | (5,175,000) | $ (4,242,000) |
Unrealized losses expected to be reclassified out of accumulated other comprehensive loss into interest expense over the next 12 months | $ 6,600,000 |
Net Income Per Share (Details) - shares shares in Thousands |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2017 |
Sep. 30, 2016 |
Sep. 30, 2017 |
Sep. 30, 2016 |
|
Reconciliation of basic to diluted weighted average shares outstanding | ||||
Basic weighted average common shares outstanding (in shares) | 62,730 | 60,937 | 62,185 | 60,579 |
Effect of dilutive stock options and RSAs/RSUs (in shares) | 3,142 | 3,584 | 3,498 | 3,689 |
Diluted weighted average common shares outstanding (in shares) | 65,872 | 64,521 | 65,683 | 64,268 |
Anti-dilutive shares (in shares) | 733 | 359 | 381 | 314 |
D@+N*$[FT_1PGKOYMSC:
M(3Y]6Z-996]3.Q?)YBS!6\E'1:4H[%62Q?ZO)E U@7,\W<87>CRI\33'F]MX
MQP9QEKA9.*ZDQ#A+3:E4C
M5AKQS(B51K#,N:R2,D,^MXEI*50WA7!#.7-3B&Y<3@5?(ZFB@DPB89SJQ4DO
MK)>-$[V4'HN"K60E904:1TYW4ZIN2NF&[;!-*;H! L-EE925SKJ$&:^:\=(,
M,3->FK%D<\LS6.J\ U_FNAW(=4#ETI @5"X3!\!Q"%2*+JZ5=XG<@00R03JR
MW!'()"V=X?M*DR$@)/SH] 24?@KN!V5'E/N"KVVE"!%\3C[E22Y@<@$, G@+2V!\%J"% _0S0'P;H(4!_=@0S
M!!@RPNS(O5_,1=F6=_.Z.DSJXW[8E]VV@QN3RK7J;O;5Z?^7UK-)=]_N;)C/
MWKH\ R0_0O ,XK)+R()#X(28I?%/DT!I$CFR<+P
?
M="#A(DL\%80Q2 "#K#%(EG#>:S-6DW*""4B @*P)2!9N PJ\SA770)BR@R%(
M-B%UK%=0LLEFG,8^-VZL+N4&\Y0 3UGSE"PG*3
[?S(?P2>ZVNE3" H\I9/]$I^:Y0YO9/H..&>D+F3L_A>3[Y^4+W+]&/S.Q'7NI'>
MB2M]X^V]O'"N0#O6]GROTI-ZW%"X*+/,]%KT\ZK?*-X.HS@8_P^*OU!+ P04
M " /5EI+X1?V"!X" "0!@ &0 'AL+W=O
; NZI*>:JF^QKU_]GLFW-['&1,#J+CAW1B'D8,.0,
M0RX12P3!)DAD!$PJ"*J"]/'T0D6"$U"4@/8$R04!L](8,*+'U#TFC;,T RL7
M%\:HB&."RTE0.0DBAUMR!@P[6^<# 0XBL?0@.$@AIAP7Q%!!#!$D+$',68AE
M5( %6[HPREC&/7(X*HO@11K;QWRW.4IIA(TF
MB>SFG.T%I)^4XFC<,+=CU7;A=F)DT]TPXOZ:L_X'4$L#!!0 ( ]66DLZ
MI_U^% , ,P- 9 >&PO=V]R:W-H965T